Laroxyl 40 mg/mL, solution buvable, Qutenza 179 mg cutaneous patch clinical trials

Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With ORL Cancer in Remission and With Sequellae Neuropathic Pain.

This study looks into whether a skin patch called Qutenza can help people who have had head and neck cancer and are left with nerve pain. It compares Qutenza with another medicine, Laroxyl, to see if either can reduce pain by a significant amount over nine months.